In this on-demand Tweetorial video from BREAST CANCER CONNECT, Dr Paolo Tarantino presents a patient with ER+/HER2- de novo metastatic breast cancer, exploring the entire diagnostic and treatment process.
Clinical Takeaways
- Guidelines recommend performing molecular testing with ctDNA to tailor treatment strategies in cases of recurrence or progression on endocrine therapy
- Elacestrant, as the first FDA-approved oral SERD (January 2023), offers a promising choice for select patients with ER+/HER2- metastatic breast cancer harbouring an ESR1 mutation
- Oral SERDs are being studied as a monotherapy and in combination with targeted therapies (i.e. CDK4/6, PI3K and AKT inhibitors), offering promising prospects for their integration into clinical practice
Duration 
Language(s)
Downloadable 
5 MIN
Aug 2024 
